期刊文献+

尾加压素Ⅱ转基因家兔制作及其影响因素分析

Creation of urotensin Ⅱ transgenic rabbits by microinjection and analysis of affecting factors
下载PDF
导出
摘要 目的分析影响转基因家兔制作的因素,优化转基因动物制作过程,建立适合本实验室的转基因家兔制作方法。方法利用显微注射方法制作转基因家兔,对超数排卵的程序、受精卵的收集、外源基因的显微注射、胚胎移植和术后护理等影响因素都进行了对比研究和探讨。结果优化了转基因家兔制作过程,通过对比发现注射卵泡刺激素方案优于注射孕马血清方案,更易获得较多数量的受精卵。PCR检验结果显示我们成功获得尾加压素Ⅱ转基因家兔。结论通过成功制作尾加压素Ⅱ转基因家兔,建立了适合本实验室的转基因家兔制作方法,同时为研究尾加压素Ⅱ生物学功能和其与疾病的关系提供了有力工具。 Objective To establish a transgenic animal method suitable for our laboratory by optimizing the factors affecting the procedure of transgenic urotesin Ⅱ(U Ⅱ) rabbits creation.Methods U Ⅱ transgenic rabbits were created by microinjection method.We compared the follicle-stimulating hormone(FSH) administration protocol and the pregnant mare serum gonadotropin(PMSG) administration protocol in collection of more zygotes.Results The results showed that the FSH administration protocol was better than the PMSG administration protocol in collection of more zygotes.We successfully established the U Ⅱ transgenic rabbits model by microinjection method.Conclusion We have successfully created UⅡ transgenic rabbits by microinjection method and provided a powerful tool for studies on U Ⅱ biological function and its relationship with diseases.
出处 《西安交通大学学报(医学版)》 CAS CSCD 北大核心 2013年第4期537-540,共4页 Journal of Xi’an Jiaotong University(Medical Sciences)
基金 国家自然科学基金和科技支撑资助项目(No.30900526 81070250和2012BAI39B02)~~
关键词 尾加压素Ⅱ 转基因 家兔 影响因素 显微注射法 urotesin Ⅱ transgene rabbit affecting factor microinjection
  • 相关文献

参考文献13

  • 1MANNING PJ, RINGLER DH, NEWCOMER CEo The biology of the laboratory rabbits [MJ. San Diego USA: Academic Press Inc, 1994:367-380.
  • 2FAN J, WATANABE T. Transgenic rabbits as therapeutic protein bioreactors and human disease models [J]. Pharmacol Ther, 2003, 99 (3): 261-82.
  • 3刘恩岐,范江霖.转基因兔在动脉粥样硬化研究中的应用及其进展[J].中国动脉硬化杂志,2003,11(4):371-375. 被引量:23
  • 4ZHAO S, WEI K, YU Q, et al. General topic: applications of transgenic rabbits in biomedical research-based on literature search [J]. World Rabbit Sci, 2010, 18(3): 159-167.
  • 5DOUGLAS SA, OHLSTEIN EH. Human urotensin-Ⅱ, the most potent mammalian vasoconstrictor identified to date, as a therapeutic target for the management of cardiovascular disease [J]. Trends Cardiovasc Med, 2000, 10(6): 229-237.
  • 6LESCOT E, SOPKOVA-DE OLIVEIRA SANTOS J, COLLOC'H N, et al. Three-dimensional model of the human urotensin-Ⅱ receptor: docking of human urotensin-Ⅱ and nonpeptide antagonists in the binding site and comparison with an antagonist pharmacophore model [J]. Proteins, 2008, 73(1):173-184.
  • 7AMES RS, SARAU HM, CHAMBERS JK, et al. Human urotensin-Ⅱ is a potent vasoconstrictor and agonist for the orphan receptor GPR14 [J]. Nature, 1999, 401 (6750) :282-286.
  • 8MAGUIRE JJ, KUC RE, WILEY KE, et al. Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries [J]. Peptides, 2004, 25(10),1767-1774.
  • 9BOUSETTE N, PATEL L, DOUGLAS SA, et al. Increased expression of urotensin II and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta [J]. Atherosclerosis, 2004,176(1):117-123.
  • 10刘恩岐,郑华东,赵四海,杨鹏辉.转基因家兔模型制作方法[J].动物学杂志,2006,41(3):62-69. 被引量:12

二级参考文献64

共引文献40

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部